Bone Marrow Molecular Markers Associated with RelapsedRefractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
Joint Authors
Wang, Di
Liu, Peng
Zhang, Yue
Liu, Hui-Ying
Shen, Di
Che, Yi-Qun
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-11-11
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is a common subtype of non-Hodgkin’s lymphoma and is very likely to infiltrate the bone marrow.
Over 30% of patients are converted to relapsed/refractory DLBCL after first-line rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, with a poor prognosis.
Our aim was to identify molecular markers that might be utilized to predict relapsed/refractory ABC-DLBCL patients.
Hence, we collected bone marrow aspirate smears from 202 patients with ABC-DLBCL and detected expression of bone marrow molecular marker proteins by immunocytochemistry.
Signal transducer and activator of transcription (Stat)3, nuclear factor (NF)-κB p65, Syk, Bruton’s tyrosine kinase (BTK), and Bcl2 proteins were strongly expressed in bone marrow aspirate smears of ABC-DLBCL patients.
The same smear could present positive expression of multiple proteins simultaneously.
Positive combinations of protein expression were associated with resistance.
The most significant finding was that the Stat3+NF-κB+ group developed resistance, which was significantly higher than that of the Stat3-NF-κB-group (80 vs.
14%).
There was a significant difference in two-year relapse-free survival between protein-positive and protein-negative combinations of Stat3-NF-κB (P = 0.005), Bcl2-Stat3 (P = 0.009), Bcl2-Pax5 (P = 0.003), and BTK-Syk (P < 0.001).
Thus, we detected key molecules in multiple signaling pathways in bone marrow aspirate smears.
At the same time, the results provide further clinical evidence of ABC-DLBCL drug-resistant molecules and provide a theoretical basis for rational second-line treatment after drug resistance.
American Psychological Association (APA)
Wang, Di& Liu, Peng& Zhang, Yue& Liu, Hui-Ying& Shen, Di& Che, Yi-Qun. 2018. Bone Marrow Molecular Markers Associated with RelapsedRefractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. BioMed Research International،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1124114
Modern Language Association (MLA)
Wang, Di…[et al.]. Bone Marrow Molecular Markers Associated with RelapsedRefractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. BioMed Research International No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1124114
American Medical Association (AMA)
Wang, Di& Liu, Peng& Zhang, Yue& Liu, Hui-Ying& Shen, Di& Che, Yi-Qun. Bone Marrow Molecular Markers Associated with RelapsedRefractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1124114
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1124114